Prostaglandin E2 receptors and their role in gastrointestinal motility - Potential therapeutic targets

被引:11
|
作者
Heeney, A. [2 ,3 ]
Rogers, A. C. [2 ,3 ]
Mohan, H. [2 ,3 ]
Mc Dermott, F. [2 ]
Baird, A. W. [2 ]
Winter, D. C. [1 ,3 ]
机构
[1] St Vincents Univ Hosp, Inst Clin Outcomes Res & Educ ICORE, Elm Pk, Dublin 4, Ireland
[2] Univ Coll Dublin, Coll Life Sci, Dept Physiol, Dublin, Ireland
[3] St Vincents Univ Hosp, Dept Surg, Elm Pk, Dublin 4, Ireland
关键词
Prostaglandin; Receptor; EP; Gastrointestinal; Motility; motor; DUODENAL BICARBONATE SECRETION; LONGITUDINAL SMOOTH-MUSCLE; PROSTANOID RECEPTORS; EP2; RECEPTOR; IN-VITRO; COLONIC MOTILITY; SMALL-INTESTINE; SELECTIVE AGONIST; MESSENGER-RNA; PHARMACOLOGICAL CHARACTERIZATION;
D O I
10.1016/j.prostaglandins.2020.106499
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostaglandin E2 (PGE2) is found throughout the gastrointestinal tract in a diverse variety of functions and roles. The recent discovery of four PGE2 receptor subtypes in intestinal muscle layers as well as in the enteric plexus has led to much interest in the study of their roles in gut motility. Gut dysmotility has been implicated in functional disease processes including irritable bowel syndrome (IBS) and slow transit constipation, and lubiprostone, a PGE2 derivative, has recently been licensed to treat both conditions. The diversity of actions of PGE2 in the intestinal tract is attributed to its differing effects on its downstream receptor types, as well as their varied distribution in the gut, in both health and disease. This review aims to identify the role and distribution of PGE2 receptors in the intestinal tract, and aims to elucidate their distinct role in gut motor function, with a specific focus on functional intestinal pathologies.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Prostaglandin E2 receptors as therapeutic targets in renal fibrosis
    Mutsaers, Henricus A. M.
    Norregaard, Rikke
    [J]. KIDNEY RESEARCH AND CLINICAL PRACTICE, 2022, 41 (01) : 4 - 13
  • [2] Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
    Jocelyn Reader
    Dawn Holt
    Amy Fulton
    [J]. Cancer and Metastasis Reviews, 2011, 30 : 449 - 463
  • [3] Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?
    O'Callaghan, G.
    Houston, A.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (22) : 5239 - 5250
  • [4] Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
    Reader, Jocelyn
    Holt, Dawn
    Fulton, Amy
    [J]. CANCER AND METASTASIS REVIEWS, 2011, 30 (3-4) : 449 - 463
  • [5] Therapeutic targets in prostaglandin E2 signaling for neurologic disease
    Cimino, P. J.
    Keene, C. Dirk
    Breyer, Richard M.
    Montine, Kathleen S.
    Montine, Thomas J.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2008, 15 (19) : 1863 - 1869
  • [6] Role of Prostaglandin E2 in the Progression of Gastrointestinal Cancer
    Wilson, David Jay
    DuBois, Raymond N.
    [J]. CANCER PREVENTION RESEARCH, 2022, 15 (06) : 355 - 364
  • [7] Significance and therapeutic potential of prostaglandin E2 receptors in liver ischemia reperfusion injury
    Kuzumoto, Y
    Sho, M
    Ikeda, N
    Hamada, K
    Mizuno, T
    Akashi, S
    Tsurui, Y
    Kashizuka, H
    Nakajima, Y
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 435 - 435
  • [8] Prostaglandin E2 as a mediator of fever:: The role of prostaglandin (EP) receptors
    Oka, T
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 : 3046 - 3057
  • [9] Mechanisms for the prevention of gastrointestinal cancer:: The role of prostaglandin E2
    Backlund, MG
    Mann, JR
    DuBois, RN
    [J]. ONCOLOGY, 2005, 69 : 28 - 32
  • [10] The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis
    McCoy, JM
    Wicks, JR
    Audoly, LP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (05): : 651 - 658